Life Science

Arachidonoyl PAF C-16 is the product of acylation of lyso-PAF C-16 by a CoA-independent transacylase. It is the most common precursor for formation of PAF C-16 by the remodeling pathway.

Arachidonoyl PAF C-16 is the product of acylation of lyso-PAF C-16 by a CoA-independent transacylase. It is the most common precursor for formation of PAF C-16 by the remodeling pathway.

Arachidonoyl PAF C-16 is the product of acylation of lyso-PAF C-16 by a CoA-independent transacylase. It is the most common precursor for formation of PAF C-16 by the remodeling pathway.

Arachidonoyl PAF C-16 is the product of acylation of lyso-PAF C-16 by a CoA-independent transacylase. It is the most common precursor for formation of PAF C-16 by the remodeling pathway.

A 2-AG analog with increased stability approximately a log less potent as a CB1 receptor agonist than 2-AG.

A 2-AG analog with increased stability approximately a log less potent as a CB1 receptor agonist than 2-AG.

A 2-AG analog with increased stability approximately a log less potent as a CB1 receptor agonist than 2-AG.

A 2-AG analog with increased stability approximately a log less potent as a CB1 receptor agonist than 2-AG.

An inhibitor of FAAH attenuating the FAAH activity from mouse neuroblastoma cells with an IC₅₀ value of 12 &microM alters both the Km and the Vmax of FAAH, indicating that it is a very tight binding, competitive inhibitor does not

An inhibitor of FAAH attenuating the FAAH activity from mouse neuroblastoma cells with an IC₅₀ value of 12 &microM alters both the Km and the Vmax of FAAH, indicating that it is a very tight binding, competitive inhibitor does not

An inhibitor of FAAH attenuating the FAAH activity from mouse neuroblastoma cells with an IC₅₀ value of 12 &microM alters both the Km and the Vmax of FAAH, indicating that it is a very tight binding, competitive inhibitor does not

A chromogenic substrate for many PLA2s including sPLA2, cPLA2, and iPLA2.